<DOC>
	<DOCNO>NCT02132572</DOCNO>
	<brief_summary>Retrospective multi-center , post-marketing study evaluate incidence etiology reoperations Allergan Natrelle® Breast Implants primary augmentation ( RANBI )</brief_summary>
	<brief_title>Retrospective Study Incidence Etiology Reoperation After Primary Augmentation With Natrelle® Breast Implants</brief_title>
	<detailed_description />
	<criteria>Primary breast augmentation ( either bilateral unilateral ) operate investigate surgeon inframammary approach 410 cohesive BIOCELL™ textured device ( Truform 2 &amp; 3 ) implant Primary breast augmentation 3 10 year prior data collection Submuscular/dual plane subglandular implant placement Breast augmentation Poland Syndrome amastia Breast reconstruction follow mastectomy Revision secondary breast reconstruction Non 410 device initial breast augmentation Women subsequently diagnose fibrocystic disease consider premalignant Procedures breast related primary breast augmentation ( e.g . excision skin lesion ) Axillary periareolar approach Glandular mastopexy augmentation ( skin excision )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>